Japan’s Astellas Pharma agreed to co-develop Vir Biotechnology’s experimental prostate cancer treatment VIR-5500 in a deal worth up to 1.37 billion.
The collaboration gives Astellas access to a promising T-cell engager therapy that has shown a 45% response rate in early-stage trials, potentially strengthening its oncology pipeline.
Key Takeaways
- Astellas pays 335 million upfront for VIR-5500 co-development rights
- Experimental drug shows 45% response rate in Phase 1 trials
- Deal includes potential 1.37 billion in milestone payments
Market reaction & context
Under the strategic collaboration announced Monday, Astellas will lead U.S. commercialization while gaining exclusive rights outside the United States 1. Vir retains an option to co-commercialize the drug in the U.S. market.
The partnership represents Astellas’ latest move to expand its prostate cancer portfolio, following its 175 million acquisition of Propella Therapeutics in November 2023 6. The Japanese pharmaceutical company already markets the blockbuster prostate cancer drug developed with Pfizer.
Detailed analysis
VIR-5500 is a PSMA-targeting T-cell engager using Vir’s proprietary PRO-XTEN dual-masked technology platform 4. The experimental treatment targets prostate-specific membrane antigen (PSMA), a protein overexpressed in prostate cancer cells.
Phase 1 trial data showed the drug achieved a 45% response rate in patients with advanced prostate cancer 4. The therapy works by directing the patient’s immune system to attack cancer cells expressing PSMA.
Financial terms
Vir will receive an upfront payment of 335 million from Astellas, with potential milestone payments totaling up to 1.37 billion 3. The deal structure allows Vir to maintain significant upside exposure while sharing development costs and risks.
Astellas will fund global development activities and handle regulatory submissions outside the United States. Both companies will share profits and losses from U.S. commercialization if Vir exercises its co-promotion option.
Strategic implications
The collaboration aligns with Astellas’ focus on building a comprehensive oncology franchise beyond its existing prostate cancer treatments. The company has been actively pursuing partnerships and acquisitions to strengthen its pipeline in targeted cancer therapies.
For Vir, the deal provides substantial funding to advance VIR-5500 through late-stage clinical trials while leveraging Astellas’ global commercial infrastructure and regulatory expertise in oncology.
Next steps
The companies plan to initiate additional clinical studies to further evaluate VIR-5500’s efficacy and safety profile. Regulatory timelines for potential approval will depend on upcoming Phase 2 and Phase 3 trial results.
The collaboration is expected to close in the first quarter of 2026, subject to customary regulatory approvals and closing conditions.
Not investment advice. For informational purposes only.
References
1(Feb 23, 2026). “Astellas collaborates with Vir to develop its experimental prostate cancer drug”. Reuters. Retrieved February 23, 2026.
2(Feb 23, 2026). “Astellas collaborates with Vir to develop experimental prostate cancer drug”. Yahoo Finance. Retrieved February 23, 2026.
3(Feb 23, 2026). “Vir Biotechnology, Astellas in 335M prostate cancer pact”. Stock Titan. Retrieved February 23, 2026.
4(Feb 23, 2026). “Vir Biotechnology: 45% response in Phase 1 prostate cancer”. Stock Titan. Retrieved February 23, 2026.
5(Nov 16, 2023). “Astellas to acquire Propella Therapeutics and its experimental prostate cancer therapy”. NC Biotech. Retrieved February 23, 2026.
6(Nov 16, 2023). “Astellas adds prostate cancer drug to pipeline via Propella acquisition”. FirstWord Pharma. Retrieved February 23, 2026.